On the safety of intravenous iron, evidence trumps conjecture

Anemia is one of the world’s most common disorders. In 2010, global anemia prevalence was 32.9%, affecting over 2.2 billion people, and iron deficiency the most common of the causes.[1][1] Oral iron, while inexpensive and effective when taken and tolerated, is frequently associated with unpleasant

[1]  A. Bircher,et al.  Hypersensitivity from intravenous iron products. , 2014, Immunology and allergy clinics of North America.

[2]  I. Macdougall,et al.  A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[3]  Seth R Flaxman,et al.  A systematic analysis of global anemia burden from 1990 to 2010. , 2014, Blood.

[4]  I. Hussain,et al.  Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia , 2013, Anemia.

[5]  N. Hevelone,et al.  Comparative rates of adverse events with different formulations of intravenous iron , 2012, American journal of hematology.

[6]  B. Myers,et al.  Comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject) and iron(III) hydroxide dextran (Cosmofer) in pregnancy , 2012, Obstetric medicine.

[7]  N. Dahl,et al.  Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia , 2011, American journal of hematology.

[8]  Catherine M. Dormitzer,et al.  Use of parenteral iron products and serious anaphylactic‐type reactions , 2010, American journal of hematology.

[9]  D. Cella,et al.  High-molecular weight iron dextran: a wolf in sheep's clothing? , 2008, Journal of the American Society of Nephrology : JASN.

[10]  J. Critchley,et al.  Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review , 2007 .

[11]  G. Chertow,et al.  Update on adverse drug events associated with parenteral iron. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  E. Barton,et al.  Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. , 2000, The American journal of medicine.

[13]  S. Fishbane,et al.  The safety of intravenous iron dextran in hemodialysis patients. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  L. Leibovici,et al.  The safety of intravenous iron preparations: systematic review and meta-analysis. , 2015, Mayo Clinic proceedings.